Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
9-phenanthrol
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
9-Phenanthrol is a selective small molecule inhibitor of the transient receptor potential melastatin 4 (TRPM4) channel, a calcium-activated non-selective cation channel. By blocking TRPM4-mediated monovalent cation influx, 9-phenanthrol prevents cell membrane depolarization and regulates intracellular calcium signaling. It is widely used as a pharmacological tool in laboratory research to study the physiological and pathological roles of TRPM4 in various systems, including cardiac rhythm, vascular smooth muscle tone, cerebral edema, and ischemic tissue injury. At higher concentrations, it has also been shown to inhibit other channels such as TMEM16A and activate KCa3.1.
- Other names
- 9-Hydroxyphenanthrene9-Phenanthrenolphenanthren-9-olphenanthren9-olphenanthren 9-ol
02
Targets
TRPM4 (Calcium-activated non-selective cation channel TRPM4)
Beyond the preview
Go deeper on 9-phenanthrol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 9-phenanthrol.